Rationale, design, and baseline characteristics of the Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection: EPIC-HIV Randomized Clinical Trial

By afschroeder • March 3, 2026

Durstenfeld MS, Levkova-Clark M, Ms DL, Schaffer V, Abohashem S, Ma Y, Kawai K, Lu MT, Sereti I, Deeks SG, Tawakol A, Hsue PY. Rationale, design, and baseline characteristics of the Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection: EPIC-HIV Randomized Clinical Trial. Am Heart J. 2026 Feb 28:107400. doi: 10.1016/j.ahj.2026.107400. Epub ahead of print. PMID: 41771366.

Tags: arterial inflammation, Cardiology/Epi, Cholesterol, Clinical Trial, Coronary Atherosclerosis, HIV, PCSK9, Publications

Fatty Acid and Oxylipin Metabolism Differentiate Isolated Postcapillary From Combined Pre- and Postcapillary Pulmonary Hypertension

Alotaibi M, Tang A, Sun N, Gurholt I, Yuguchi E, Roberts K, Preston I, Warburton R, Yuan JX, Kim NH, Chan SY, Jain M, Cheng[...]

Artificial intelligence-enabled electrocardiography for detection of left ventricular diastolic dysfunction: a systematic review and meta-analysis

Edjimbi J, Shah N, Donisi L, Gajjar A, See C, Grimshaw AA, Diop HB, Ribeiro ALP, Marijon E, Clifford G, Gaye B. Artificial intelligence-enabled electrocardiography[...]

Heart failure among people with HIV: prescription of guideline-directed medical therapy

Cutshaw MK, Clare R, Chiswell K, Hofmann P, Pettit AC, Meissner E, Durstenfeld MS, Longenecker CT, Bloomfield GS, Okeke NL. Heart failure among people with[...]